Novo Nordisk shares were under pressure on Monday as the struggling Danish pharmaceutical said a head-to-head study found a drug in development didn’t cut as much weight as an Eli Lilly product.
Source link
Novo Nordisk’s stock slips to 4-year low after its next-gen weight-loss drug lost to Lilly’s in Phase 3 trial
